BLEFASTOP (Ophthalmology - Blepharitis)

BLEFASTOP (Ophthalmology - Blepharitis)
Product Description

The product has been specifically formulated as an adjuvant in blepharitis treatment. This product contains a derivative of Tea Tree Oil (Terpinen-4-ol) characterized by an anti-inflammatory, antimicrobial and acaricidal activity against Staphylococcus aureus and Demodex (either directly or by carrying bacteria). The product contains also Hyaluronic acid that is able to lubricate, moisturize and protect the ocular surface and, forming a complex with T-4-ol, also contributes to create a soft wipe, very suitable for cleaning the eye zone.
- Presentation: disposable wipes contain Hy-Ter solution + warming compress for posterior blepharitis.
- Class: Medical Device 
- CE Mark expiry date: 2024 1 Scientific publication available - IP protected.


NTC S.r.l.

  • Country/Region:
    Italy
  • On CPHI since:
    2015
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
Pharmaceutical company
Primary activities
Pharmaceutical Company (innovator finished products)
Specifications
  • Selling Points
    Product Features; Product Performance
  • Supplied from
    Italy

NTC S.r.l.

  • Country/Region:
    Italy
  • On CPHI since:
    2015
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
Pharmaceutical company
Primary activities
Pharmaceutical Company (innovator finished products)

More Products from NTC S.r.l. (29)

NTC S.r.l. resources (8)

  • News A pharmacovigilance study published confirms the safety of fixed-dose eye drops for post-cataract surgery

    A pharmacovigilance study published confirms the safety of fixed-dose eye drops for post-cataract surgery 17 Jul, 2025A recently published five-year pharmacovigilance study confirms the excellent safety profile of a fixed-dose combination eye drop containing an anti-inflammatory steroid and a quinolone antibiotic, developed by NTC, indicated for the prevention and treatment of inflammation and prevention of infection following cataract surgery in adults. The study was submitted when nearly 4 million patients across about 60 countries worldwide were treated with this drug.

     

  • Brochure Therapeutical areas - brochure

    Advanced scientific research and technology drive our efforts to innovate care practices.
    Our range of products builds from our historical vocation for innovation aimed at improving the experience of patients and healthcare practices.
    An innovation aimed at discovering specific therapeutic gestures: simple and intuitive,  sustainable, and technically advanced for empowering the patient.
    Our research aims to put pioneering new products within the reach of everyone and to optimize the
    performance of our products by analyzing the daily needs and habits of people undergoing treatment.
    We research, develop and produce innovative drugs, medical devices and food supplements.
    We market our products worldwide through licensing, distribution, marketing, and commercial deals with partner companies.
    Our core therapeutic areas are: Ophthalmology, Gastro-Metabolism, Pediatrics and Gynacology.

  • News New ally against antibiotic-resistant skin infections: TiAB shows promising results

    A new in vitro study shows that a 2% concentration of TiAB—a compound based on silver-bound titanium dioxide—is sufficient to exert strong bactericidal activity within 24 hours against Gram-negative bacteria and support wound healing.
  • Report Value Report 2025

    It describes our 2024 journey